FOR AMD PATIENTS WITH PREDOMINANTLY CLASSIC NEOVASCULAR LESIONS WHO EXPERIENCE PERSISTENT DISEASE ACTIVITY

MEET THESE TREATMENT CHALLENGES WITH VISUDYNE®

Persistent activity may continue despite anti-VEGF therapy–that's where VISUDYNE® comes in

VISUDYNE® Physician Finder

If you feel that VISUDYNE® treatment is right for your patient, find a doctor equipped to administer and activate VISUDYNE® here

About VISUDYNE®

VISUDYNE® is a photosensitizer drug that is activated through direct laser excitation, delivering a targeted approach that specifically destroys abnormal choroidal blood vessels to help prevent further disease progression and help patients maintain their vision¹

VISUDYNE® offers an anatomical treatment that also occludes mature vessels that may be expressing less or no VEGF¹

25% of wet AMD patients have clinically significant persistent disease activity (PDA) even after 1 year of anti-VEGF therapy²*

*As observed in a single "real-world" retina practice, and not in a clinical trial

Consider VISUDYNE® for wet AMD patients who suffer from persistent intraocular fluid leakage, including anti-VEGF non-responders–who need a targeted solution

Learn About Efficacy and Safety of VISUDYNE®
Learn About Efficacy and Safety of VISUDYNE®

Indication

VISUDYNE® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Important Safety Information

  • VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
  • Standard precautions should be taken during infusion of VISUDYNE® to avoid extravasation, including but not limited to:
    • A free-flowing intravenous (IV) line should be established before starting VISUDYNE® infusion and the line should be carefully monitored.
    • Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible, preferably the antecubital, be used for injection.
    • Small veins in the back of the hand should be avoided.
  • Extravasation of VISUDYNE®, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site. If extravasation does occur, the infusion should be stopped immediately. The extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of local burn, which could be severe. Cold compresses should be applied to the injection site. Oral medication for pain relief may be administered.
  • Following injection with VISUDYNE®, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
  • Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician.
  • The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including scotoma).

Click here for full Prescribing Information for VISUDYNE®.

References: 1. VISUDYNE [package insert], Bausch & Lomb Incorporated. 2. Cousins SW. Controversies in long-term AMD management: the role of imaging in clinical decision making. Retinal Physician. 2010. https://www.retinalphysician.com/issues/2010/jan-feb/controversies-in-the-long-term-management-of-neova. Accessed November 2, 2017.

Indication and Important Safety Information